![](https://media.americanpharmaceuticalreview.com/m/28/article/617632.jpg)
OliX and Lilly Partner on MASH and Other Cardiometabolic Indications
OliX Pharmaceuticals, Inc. announced a global licensing agreement with Eli Lilly and Company. This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated …